Clinical trial · Observational

The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring

NCT02647164CI-TRIAL-00020441unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The time of CTC and carcinoembryonic antigen(CEA) detection is baseline, 2\~7 days, 3 months, 6 months, 12 months, 24 months, 36 months after the surgery. And the time of CT detection is 6 months, 12 months, 24 months, 36 months after the surgery.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Non-small-cell Lung Carcinoma	Lung Non-Small Cell Carcinoma	ALIAS	0.90

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Circulating tumor cells will be detected by Immunomagnetic negative screening and targeted PCR method.
timeFrame
3 years

Secondary outcomes (2)

measure
carcinoembryonic antigen(CEA) concentration will be detected by electrochemical luminescence.
timeFrame
3 years
measure
Liconography using conventional CT examination results.
timeFrame
3 years

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 80 Years

Show eligibility criteria text

Inclusion Criteria:

* Age 18-80 years old
* Patients with histologically documented (stage Ⅰ/Ⅱ/ⅢA ) non-small cell lung cancer.
* Patients will undergo surgery.
* Patients with preoperative CTCs ≥8.5 Units / 3 ml
* Informed consent must be obtained from all patients prior to beginning therapy. Patients should have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients with histologically documented not (stage Ⅰ/Ⅱ/ⅢA ) non-small cell lung cancer.
* After the operation review, patients' result of CTC, CT and tumor markers is incomplete at the same point.
* The blood sample isn't collected in predetermined time.
* The blood samples appear hemolysis.
* The blood sample isn't enough.

References

Publications (0)

Data not yet available

No reference posted for this study.